Cargando…
Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6
SIMPLE SUMMARY: The most successful strategies for solid cancer immunotherapy have centered on targeting the co-stimulatory and co-inhibitory T cell molecules that regulate T cell activation. Although immunotherapy that targets surface receptors such as CTLA-4 and/or PD-1 with recombinant antibodies...
Autores principales: | Klepsch, Victoria, Siegmund, Kerstin, Baier, Gottfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197903/ https://www.ncbi.nlm.nih.gov/pubmed/34073258 http://dx.doi.org/10.3390/cancers13112600 |
Ejemplares similares
-
The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance
por: Hermann-Kleiter, Natascha, et al.
Publicado: (2015) -
Loss of the orphan nuclear receptor NR2F6 enhances CD8(+) T-cell memory via IFN-γ
por: Jakic, Bojana, et al.
Publicado: (2021) -
Nuclear orphan receptor NR2F6 as a safeguard against experimental murine colitis
por: Klepsch, Victoria, et al.
Publicado: (2018) -
Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy
por: Klepsch, Victoria, et al.
Publicado: (2020) -
Orphan Nuclear Receptor NR2F6 Suppresses T Follicular Helper Cell Accumulation through Regulation of IL-21
por: Olson, William J., et al.
Publicado: (2019)